All Change in the US Pharma Market? : Market Research Report

All Change in the US Pharma Market?

Published by: Espicom Healthcare Intelligence

Published: Jun. 18, 2008 - 186 Pages

Foreword
EXECUTIVE SUMMARY
Industry Overview
Branded company sales overview: Leading Originator Companies, Global Pharmaceutical Revenues, 2006-07 (US$ millions)
Exposure to generics: % of Global Revenues Likely to Face Generic Competition, 2008-12
Branded defence strategies: Incremental innovation; Extended-release formulations; Second-generation products; Citizen petitions; Deals with generic companies; Authorised generics
Biologics: Leading Originator Companies, PHSA Biologic Revenues 2007; FDCA biologics
Generic Approvals and Launches: Pharmaceutical Products Estimated to Face Widespread Generic Competition by 2012; Pharmaceutical Products Estimated to Face Limited Generic Competition by 2012; Pharmaceutical Products Estimated to Face No Generic Competition by 2012; Biologic Products: No Generic Competition to 2012; 2007 Global Revenues Subject to Generic Competition by 2012 (US$ millions); Generic launches „at risk‟; Summary of „at risk‟ US Generic Launches, 2006-08
Research-Based Company Profiles
Abbott Laboratories: Sales Intro; Exposure to generics 2008-12; Defence strategies; Biaxin; Depakote/Depakote ER; Humira; Kaletra; Omnicef; Synthroid; Tricor
Amgen: Sales Intro; Exposure to generics 2008-12; Defence strategies; Aranesp; Epogen; Neulasta; Neupogen; Enbrel; Sensipar; Vectibix
AstraZeneca: Sales Intro; Exposure to generics 2008-12; Defence Strategies; Arimidex; Atacand; Casodex; Crestor; Nexium; Prilosec; Pulmicort; Seroquel; Toprol XL; Zoladex; Zomig
Boehringer Ingelheim: Sales Intro; Exposure to generics 2008-12; Defence strategies; Aggrenox; Combivent; Flomax; Micardis; Mirapex; Mobic; Spiriva
Bristol-Myers Squibb: Sales Intro; Exposure to generics 2008-12; Defence strategies; Abilify; Avapro/Avalide; Baraclude; Erbitux; Orencia; Plavix; Pravachol; Reyataz; Sprycel; Sustiva
Eli Lilly: Sales Intro; Exposure to generics 2008-12
Defence strategies: Alimta; Byetta; Cialis; Cymbalta; Evista; Forteo; Gemzar; Humatrope; Strattera; Zyprexa; Insulin products
GlaxoSmithKline: Sales Intro; Exposure to generics 2008-12; Defence strategies; Advair Diskus; Augmentin; Avandia; Avodart; Combivir; Coreg; Epzicom; Flonase; Flovent; Imitrex; Lamictal; Paxil; Requip; Trizivir; Valtrex; Wellbutrin; Zofran
Johnson & Johnson: Sales intro; Exposure to generics 2008-12; Defence strategies; Aciphex; Concerta; Duragesic; Levaquin; Procrit; Remicade; Risperdal; Topamax
Merck & Co: Sales intro; Exposure to generics 2008-12; Defence strategies; Cancidas; Cozaar; Emend; Fosamax; Januvia; Maxalt; Primaxin; Proscar/Propecia; Singulair; Trusopt/Cosopt; Zocor
Novartis: Sales intro; Exposure to generics 2008-12; Defence strategies; Diovan; Exelon; Famvir; Femara; Focalin; Gleevec; Lamisil; Lescol XL; Lotrel; Sandostatin; Trileptal; Zometa
Pfizer: Sales Intro; Exposure to generics 2008-12; Defence strategies; Aricept; Aromasin; Caduet; Camptosar; Cardura; Celebrex; Chantix; Detrol/Detrol LA; Genotropin; Geodon Oral; Lipitor; Lyrica; Neurontin; Norvasc; Relpax; Sutent; Vfend; Viagra/Revatio; Xalatan; Zithromax; Zoloft; Zyrtec; Zyvox
Roche: Sales intro; Exposure to generics 2008-12; Defence strategies; Avastin; Boniva; CellCept; Herceptin; Kytril; Lucentis; Nutropin; Pegasys; Rituxan; Tamiflu; Tarceva; Valcyte; Xeloda; Xenical; Xolair
Sanofi Aventis: Sales intro; Exposure to generics 2008-12; Defence strategies; Actonel; Allegra; Amaryl; Ambien; Avapro; Copaxone; Deprocon; Eloxatine; Lantus; Lovenox; Nasacort; Plavix; Taxotere; Altace; Uroxatral
Wyeth: Sales intro; Exposure to generics 2008-12; Defence strategies; Effexor; Prevnar; Protonix; Zosyn/Tazocin; Tygacil
Appendix: Overview of the generic application and approval system
Appendix 1: ANDA Approvals: ANDA Approvals, 2002-08

Abstract

This extensive report provides a unique analysis of the likely impact of generic competition in the US pharma market. Now you can...

Identify the 150 products which could be subject to generic competition over the next 5 years

Evaluate the level of impact on each product

Assess the impact of generic competition on 14 leading branded companies

Understand the strategies being used by companies in defence of their products’ position
Key questions answered in this report

Which companies are at greater or lesser risk of generic competition by 2012 and what will be the impact on revenues?

What strategies has Abbott successfully employed in defence of Depakote and Tricor?

Who is benefiting from the unresolved biosimilar approval process?

AstraZeneca could have US$5.31 billion of revenue at risk by 2012 - what are the products affected and when will the impact be felt?

What lessons can be learned from the ongoing Apotex/BMS and SA litigation in relation to the world’s second best selling drug Plavix?

There is much discussion about generic competition to Lipitor, but what other products are at risk in Pfizer’s portfolio?

Why has Wyeth not sued Sun Pharmaceutical over its extended release tablet for Effexor?

Understand the developments that are driving change
All Change in the US Pharma Market?
The rise of generics, products at risk and defence strategies

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

All Change in the US Pharma Market?

Table of Contents

Abstract